Davide Campana

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4605317/publications.pdf

Version: 2024-02-01

134	3,945	117625	133252
papers	citations	34	59
		h-index	g-index

137	137	137	4035
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Metastatic and Locally Advanced Pancreatic Endocrine Carcinomas: Analysis of Factors Associated With Disease Progression. Journal of Clinical Oncology, 2011, 29, 2372-2377.	1.6	261
2	Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 1431-1438.	6.4	254
3	⁶⁸Ga-DOTANOC PET/CT Clinical Impact in Patients with Neuroendocrine Tumors. Journal of Nuclear Medicine, 2010, 51, 669-673.	5.0	227
4	Chromogranin A: Is It a Useful Marker of Neuroendocrine Tumors?. Journal of Clinical Oncology, 2007, 25, 1967-1973.	1.6	211
5	Endocrine pancreatic tumors: factors correlated with survival. Annals of Oncology, 2005, 16, 1806-1810.	1.2	179
6	Standardized Uptake Values of ⁶⁸Ga-DOTANOC PET: A Promising Prognostic Tool in Neuroendocrine Tumors. Journal of Nuclear Medicine, 2010, 51, 353-359.	5.0	161
7	68Ga-labelled peptides for diagnosis of gastroenteropancreatic NET. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 52-60.	6.4	112
8	68Ga-DOTA-NOC PET/CT in comparison with CT for the detection of bone metastasis in patients with neuroendocrine tumours. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 722-727.	6.4	107
9	Real-World Study of Everolimus in Advanced Progressive Neuroendocrine Tumors. Oncologist, 2014, 19, 966-974.	3.7	84
10	Warm Water or Oil-Assisted Colonoscopy: Toward Simpler Examinations?. American Journal of Gastroenterology, 2008, 103, 581-587.	0.4	81
11	Prognostic Value of ⁶⁸Ga-DOTANOC PET/CT SUV_{max} in Patients with Neuroendocrine Tumors of the Pancreas. Journal of Nuclear Medicine, 2015, 56, 1843-1848.	5.0	78
12	Prognostic factors in ectopic Cushingâ€™s syndrome due to neuroendocrine tumors: a multicenter study. European Journal of Endocrinology, 2017, 176, 453-461.	3.7	66
13	Natural history of gastro-entero-pancreatic and thoracic neuroendocrine tumors. Data from a large prospective and retrospective Italian epidemiological study: the NET management study. Journal of Endocrinological Investigation, 2012, 35, 817-23.	3.3	64
14	Gastric endocrine tumors type I: treatment with long-acting somatostatin analogs. Endocrine-Related Cancer, 2008, 15, 337-342.	3.1	62
15	Pancreatic Endocrine Tumors Less Than 4 cm in Diameter. Pancreas, 2010, 39, 825-828.	1.1	62
16	Activity & safety of spartalizumab (PDR001) in patients (pts) with advanced neuroendocrine tumors (NET) of pancreatic (Pan), gastrointestinal (GI), or thoracic (T) origin, & gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) who have progressed on prior treatment (Tx). Annals of Oncology, 2018, 29, viii467-viii468.	1.2	61
17	Assessment of the quality of life in chronic pancreatitis using Sf-12 and EORTC Qlq-C30 questionnaires. Digestive and Liver Disease, 2007, 39, 1077-1086.	0.9	60
18	Correlation between MGMT promoter methylation and response to temozolomide-based therapy in neuroendocrine neoplasms: an observational retrospective multicenter study. Endocrine, 2018, 60, 490-498.	2.3	59

#	Article	IF	Citations
19	Risk Factors for Disease Progression in Advanced Jejunoileal Neuroendocrine Tumors. Neuroendocrinology, 2012, 96, 32-40.	2.5	55
20	Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues. Gastroenterology, 2018, 155, 479-489.e7.	1.3	54
21	Everolimus in Pancreatic Neuroendocrine Carcinomas G3. Pancreas, 2017, 46, 302-305.	1.1	53
22	Radiolabelled somatostatin analogue treatment in gastroenteropancreatic neuroendocrine tumours: factors associated with response and suggestions for therapeutic sequence. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 1197-1205.	6.4	50
23	Chromogranin A: From Laboratory to Clinical Aspects of Patients with Neuroendocrine Tumors. International Journal of Endocrinology, 2018, 2018, 1-12.	1.5	49
24	Advanced Digestive Neuroendocrine Tumors. Pancreas, 2014, 43, 212-218.	1.1	46
25	Role of 18F-dopa PET/CT imaging in the management of patients with 111In-pentetreotide negative GEP tumours. Nuclear Medicine Communications, 2007, 28, 473-477.	1.1	45
26	Morphological Factors Related to Nodal Metastases in Neuroendocrine Tumors of the Appendix. Annals of Surgery, 2020, 271, 527-533.	4.2	44
27	The Role of mTOR in Neuroendocrine Tumors: Future Cornerstone of a Winning Strategy?. International Journal of Molecular Sciences, 2018, 19, 747.	4.1	42
28	Endocrine Tumors of the Ileum: Factors Correlated with Survival. Neuroendocrinology, 2006, 83, 380-386.	2.5	41
29	Clinical management of patients with gastric neuroendocrine neoplasms associated with chronic atrophic gastritis: a retrospective, multicentre study. Endocrine, 2016, 51, 131-139.	2.3	40
30	Sporadic Small (â‰20Âmm) Nonfunctioning Pancreatic Neuroendocrine Neoplasm: is the Risk of Malignancy Negligible When Adopting a More Conservative Strategy? A Systematic Review and Meta-analysis. Annals of Surgical Oncology, 2017, 24, 2603-2610.	1.5	39
31	Heterogeneity of Duodenal Neuroendocrine Tumors: An Italian Multi-center Experience. Annals of Surgical Oncology, 2018, 25, 3200-3206.	1.5	39
32	Are There Prognostic Factors Related to Recurrence in Pancreatic Endocrine Tumors?. Pancreatology, 2010, 10, 33-38.	1.1	38
33	PET/CT with 68Gallium-DOTA-peptides in NET: An overview. European Journal of Radiology, 2011, 80, e116-e119.	2.6	38
34	Serum leptin, but not adiponectin and receptor for advanced glycation end products, is able to distinguish autoimmune pancreatitis from both chronic pancreatitis and pancreatic neoplasms. Scandinavian Journal of Gastroenterology, 2010, 45, 93-99.	1.5	34
35	Is 68Ga-DOTA-NOC PET/CT indicated in patients with clinical, biochemical or radiological suspicion of neuroendocrine tumour?. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 1278-1283.	6.4	34
36	Patient-reported outcomes in subjects with neuroendocrine tumors of the pancreas. World Journal of Gastroenterology, 2009, 15, 5067.	3.3	33

#	Article	IF	Citations
37	Tumour type and size are prognostic factors in gastric neuroendocrine neoplasia: A multicentre retrospective study. Digestive and Liver Disease, 2019, 51, 1456-1460.	0.9	32
38	Nonconventional Doses of Somatostatin Analogs in Patients With Progressing Well-Differentiated Neuroendocrine Tumor. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 194-200.	3.6	32
39	The functioning side of the pancreas: a review on insulinomas. Journal of Endocrinological Investigation, 2020, 43, 139-148.	3.3	32
40	Risk factors of type 1 gastric neuroendocrine neoplasia in patients with chronic atrophic gastritis. A retrospective, multicentre study. Endocrine, 2017, 56, 633-638.	2.3	30
41	Quality of life in chronic pancreatitis. World Journal of Gastroenterology, 2006, 12, 6249.	3.3	29
42	Fecal calprotectin and elastase 1 determinations in patients with pancreatic diseases: a possible link between pancreatic insufficiency and intestinal inflammation. Journal of Gastroenterology, 2007, 42, 754-760.	5.1	28
43	Risk and Protective Factors for Small Intestine Neuroendocrine Tumors: A Prospective Case-Control Study. Neuroendocrinology, 2016, 103, 531-537.	2.5	28
44	Biliary stone disease in patients receiving somatostatin analogs for neuroendocrine neoplasms. A retrospective observational study. Digestive and Liver Disease, 2019, 51, 689-694.	0.9	27
45	Biliary Stone Disease in Patients with Neuroendocrine Tumors Treated with Somatostatin Analogs: A Multicenter Study. Oncologist, 2020, 25, 259-265.	3.7	27
46	Landscape and Future Perspectives of Immunotherapy in Neuroendocrine Neoplasia. Cancers, 2020, 12, 832.	3.7	27
47	Plasma acylated ghrelin levels are higher in patients with chronic atrophic gastritis. Clinical Endocrinology, 2007, 67, 761-766.	2.4	26
48	Chronic asymptomatic pancreatic hyperenzymemia is a benign condition in only half of the cases: A prospective study. Scandinavian Journal of Gastroenterology, 2009, 44, 888-893.	1.5	25
49	The role of lymph node ratio in recurrence after curative surgery for pancreatic endocrine tumours. Pancreatology, 2013, 13, 589-593.	1.1	25
50	Validation of the 2010 WHO classification and a new prognostic proposal: A single centre retrospective study of well-differentiated pancreatic neuroendocrine tumours. Pancreatology, 2016, 16, 403-410.	1.1	24
51	Clinicoâ€“pathological features, treatments and survival of malignant insulinomas: a multicenter study. European Journal of Endocrinology, 2020, 182, 439-446.	3.7	24
52	Adult coeliac disease diagnosed by endoscopic biopsies in the duodenal bulb. European Journal of Gastroenterology and Hepatology, 2005, 17, 1413-1415.	1.6	22
53	68Ga-DOTA-NOC PET/CT Detects Somatostatin Receptors Expression in von Hippel-Lindau Cerebellar Disease. Clinical Nuclear Medicine, 2011, 36, 64-65.	1.3	21
54	Association of Upfront Peptide Receptor Radionuclide Therapy With Progression-Free Survival Among Patients With Enteropancreatic Neuroendocrine Tumors. JAMA Network Open, 2022, 5, e220290.	5.9	21

#	Article	IF	Citations
55	Treatment of Zollinger-Ellison Syndrome. World Journal of Gastroenterology, 2005, 11, 5423.	3.3	20
56	Large Cell Neuroendocrine Carcinoma of the Lung: Current Understanding and Challenges. Journal of Clinical Medicine, 2022, 11, 1461.	2.4	20
57	Value of Both WHO and TNM Classification Systems for Patients with Pancreatic Endocrine Tumors: Results of a Singleâ€Center Series. World Journal of Surgery, 2009, 33, 2458-2463.	1.6	19
58	Immunobiology of Thymic Epithelial Tumors: Implications for Immunotherapy with Immune Checkpoint Inhibitors. International Journal of Molecular Sciences, 2020, 21, 9056.	4.1	19
59	Sunitinib in patients with pre-treated pancreatic neuroendocrine tumors: A real-world study. Pancreatology, 2018, 18, 198-203.	1.1	18
60	A classification prognostic score to predict OS in stage IV well-differentiated neuroendocrine tumors. Endocrine-Related Cancer, 2018, 25, 607-618.	3.1	18
61	Evaluation of Patient-Reported Outcome in Subjects Treated Medically for Acute Pancreatitis: A Follow-Up Study. Pancreatology, 2009, 9, 375-382.	1.1	17
62	Radiolabeled Somatostatin Analogues for Diagnosis and Treatment of Neuroendocrine Tumors. Cancers, 2022, 14, 1055.	3.7	17
63	Treatment of malignant pancreatic neuroendocrine neoplasms: middle-term (2-year) outcomes of a prospective observational multicentre study. Hpb, 2013, 15, 935-943.	0.3	16
64	Is surgery the best treatment for sporadic small (â‰¤2Âcm) non-functioning pancreatic neuroendocrine tumours? A single centre experience. Pancreatology, 2017, 17, 471-477.	1.1	16
65	Histopathological diagnosis of appendiceal neuroendocrine neoplasms: when to perform a right hemicolectomy? A systematic review and meta-analysis. Endocrine, 2019, 66, 460-466.	2.3	16
66	Pancreatic involvement in systemic sarcoidosis. Digestive and Liver Disease, 2004, 36, 222-227.	0.9	15
67	WHO 2010 classification of pancreatic endocrine tumors. Is the new always better than the old?. Pancreatology, 2014, 14, 539-541.	1.1	15
68	Prognostic impact of tumour burden in stage IV neuroendocrine neoplasia: A comparison between pancreatic and gastrointestinal localizations. Pancreatology, 2019, 19, 1067-1073.	1.1	15
69	Gastro-entero-pancreatic neuroendocrine neoplasia: The rules for non-operative management. Surgical Oncology, 2020, 35, 141-148.	1.6	14
70	Is radical surgery always curative in pancreatic neuroendocrine tumors? A cure model survival analysis. Pancreatology, 2018, 18, 313-317.	1.1	13
71	An Overview on Molecular Characterization of Thymic Tumors: Old and New Targets for Clinical Advances. Pharmaceuticals, 2021, 14, 316.	3.8	13
72	A [68Ga]Ga-DOTANOC PET/CT Radiomic Model for Non-Invasive Prediction of Tumour Grade in Pancreatic Neuroendocrine Tumours. Diagnostics, 2021, 11, 870.	2.6	13

#	Article	IF	Citations
73	The ELISA Fecal Elastase-1 Polyclonal Assay Reacts With Different Antigens Than Those of the Monoclonal Assay. Pancreas, 2005, 31, 200-201.	1.1	11
74	Treatment of Advanced Gastro-Entero-Pancreatic Neuro-Endocrine Tumors: A Systematic Review and Network Meta-Analysis of Phase III Randomized Controlled Trials. Cancers, 2021, 13, 358.	3.7	11
75	Efficacy and Cost-Effectiveness of Immediate Surgery versus a Wait-and-See Strategy for Sporadic Nonfunctioning T1 Pancreatic Endocrine Neoplasms. Neuroendocrinology, 2015, 101, 25-34.	2.5	10
76	Temozolomide alone or in combination with capecitabine in patients with advanced neuroendocrine neoplasms: an Italian multicenter real-world analysis. Endocrine, 2021, 72, 268-278.	2.3	10
77	68Ga DOTANOC PET/CT Detects Primary Malignant Insulinoma. Clinical Nuclear Medicine, 2015, 40, e132-e133.	1.3	9
78	Incidental diagnosis of very small rectal neuroendocrine neoplasms: when should endoscopic submucosal dissection be performed? A single ENETS centre experience. Endocrine, 2019, 65, 207-212.	2.3	9
79	Role of [18F]FDG PET/CT in the management of G1 gastro-entero-pancreatic neuroendocrine tumors. Endocrine, 2022, 76, 484-490.	2.3	8
80	Maffucci Syndrome with Hemangioma of the Liver. Case Reports in Gastroenterology, 2009, 3, 1-4.	0.6	7
81	Acute leukaemia following low dose peptide receptor radionuclide therapy for an intestinal carcinoid. Digestive and Liver Disease, 2010, 42, 457-458.	0.9	7
82	Determination of Mammalian Target of Rapamycin Hyperactivation as Prognostic Factor in Well-Differentiated Neuroendocrine Tumors. Gastroenterology Research and Practice, 2017, 2017, 1-9.	1.5	7
83	Good performance of platinum-based chemotherapy for high-grade gastroenteropancreatic and unknown primary neuroendocrine neoplasms. Journal of Chemotherapy, 2018, 30, 53-58.	1.5	7
84	Factors Related to Long-Term Survival in Patients Affected by Well-Differentiated Endocrine Tumors of the Pancreas. ISRN Surgery, 2012, 2012, 1-5.	1.4	6
85	Disease-free survival as a measure of overall survival in resected pancreatic endocrine neoplasms. Endocrine-Related Cancer, 2020, 27, 275-283.	3.1	6
86	Assessment of the Risk of Nodal Involvement in Rectal Neuroendocrine Neoplasms: The NOVARA Score, a Multicentre Retrospective Study. Journal of Clinical Medicine, 2022, 11, 713.	2.4	6
87	Diagnostic value of tumor M2-pyruvate kinase in neuroendocrine tumors. A comparative study with chromogranin A. Anticancer Research, 2003, 23, 2969-72.	1.1	6
88	Lymph node ratio predicts efficacy of postoperative radiation therapy in nonmetastatic Merkel cell carcinoma: A populationâ€based analysis. Cancer Medicine, 2022, 11, 4204-4213.	2.8	6
89	When Should F-18 FDG PET/CT Be Used Instead of 68Ga-DOTA-Peptides to Investigate Metastatic Neuroendocrine Tumors?. Clinical Nuclear Medicine, 2011, 36, 1109-1111.	1.3	5
90	Therapeutic options in lung neuroendocrine tumors. Anti-Cancer Drugs, 2019, 30, 649-654.	1.4	5

#	Article	IF	Citations
91	Perioperative Chemotherapy in Poorly Differentiated Neuroendocrine Neoplasia of the Bladder: A Multicenter Analysis. Journal of Clinical Medicine, 2020, 9, 1351.	2.4	5
92	Hyperammonemic encephalopathy during XELOX regimen. Is it capecitabine or oxaliplatin responsible?. Anti-Cancer Drugs, 2020, 31, 1103-1105.	1.4	5
93	Lubrication during colonoscopy: A forgotten factor. Digestive and Liver Disease, 2005, 37, 630-631.	0.9	4
94	Comment on â€œCurrent Management and Predictive Factors of Lymph Node Metastasis of Appendix Neuroendocrine Tumorsâ€•A National Study From the French Group of Endocrine Tumors (GTE). Annals of Surgery, 2019, 270, e43-e44.	4.2	4
95	Survival after active surveillance versus upfront surgery for incidental small pancreatic neuroendocrine tumours. British Journal of Surgery, 2022, 109, 733-738.	0.3	4
96	A Meal Stimulation Test in the Diagnosis of Pancreatic Endocrine Tumors in Multiple Endocrine Neoplasia Type 1. Endocrine, 2002, 17, 229-232.	2.2	3
97	Optimal Treatment of Zollinger-Ellison Syndrome and Related Conditions in Elderly Patients. Drugs and Aging, 2003, 20, 1019-1034.	2.7	3
98	Basis for treatment of functioning neuroendocrine tumours. Digestive and Liver Disease, 2004, 36, S35-S41.	0.9	3
99	Should we lose hope in adjuvant therapy for neuroendocrine tumors?â€”In response to: Adjuvant therapy following resection of gastroenteropancreatic neuroendocrine tumors provides no recurrence or survival benefit. Journal of Surgical Oncology, 2020, 122, 570-571.	1.7	3
100	Peptide receptor radionuclide therapy for GEP-NET: consolidated knowledge and innovative applications. Clinical and Translational Imaging, 2021, 9, 423-438.	2.1	3
101	Multimodal Strategy in Localized Merkel Cell Carcinoma: Where Are We and Where Are We Heading?. International Journal of Molecular Sciences, 2021, 22, 10629.	4.1	3
102	Patient-reported outcomes in patients with endocrine tumors of the ileum. European Journal of Gastroenterology and Hepatology, 2009, 22, 1.	1.6	3
103	The 3-Dimensional-Computed Tomography Texture Is Useful to Predict Pancreatic Neuroendocrine Tumor Grading. Pancreas, 2021, 50, 1392-1399.	1.1	3
104	Duodenal Gastric Metaplasia and Duodenal Neuroendocrine Neoplasms: More Than a Simple Coincidence?. Journal of Clinical Medicine, 2022, 11, 2658.	2.4	3
105	Multiple gastric endocrine tumours and gastrinomas of the duodenum in a patient with ZES MEN 1. Digestive and Liver Disease, 2008, 40, 476.	0.9	2
106	Cutaneous Scapular Lesion in an Elderly Woman. JAMA Oncology, 2019, 5, 1355.	7.1	2
107	68Ga-DOTANOC PET/CT Detects Multifocal Hepatocellular Carcinoma. Clinical Nuclear Medicine, 2019, 44, 238-239.	1.3	2
108	Sedation during colonoscopy and the benefits of lubrication. Alimentary Pharmacology and Therapeutics, 2008, 27, 207-208.	3.7	1

#	Article	IF	Citations
109	Sedation on demand and lubrication during colonoscopy: should we change our minds?. Gastrointestinal Endoscopy, 2008, 68, 1028-1029.	1.0	1
110	Water-related techniques in colonoscopy: the end justifies the means!. Gastrointestinal Endoscopy, 2009, 70, 1287-1289.	1.0	1
111	Warm Water and Oil Assistance in Colonoscopy. Digestive Diseases and Sciences, 2010, 55, 3286-3288.	2.3	1
112	An acute and severe immunodeficiency syndrome due to a pancreatic ACTH-producing tumor. Emergency Care Journal, 2012, 8, 19.	0.3	1
113	Multiple gastrinomas of the duodenum in a patient with sporadic Zollinger-Ellison syndrome. Endocrine, 2013, 44, 815-816.	2.3	1
114	Radiolabelled somatostatin analogue treatment in gastroenteropancreatic neuroendocrine tumours: factors associated with response and suggestions for therapeutic sequence: response to comments by Ezziddin et al.. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 176-177.	6.4	1
115	Assessing safety and activity of cabozantinib combined with lanreotide in gastroenteropancreatic (GEP) and thoracic neuroendocrine tumors (NETs): The phase II LOLA trial.. Journal of Clinical Oncology, 2021, 39, TPS4167-TPS4167.	1.6	1
116	Medical treatment of endocrine gastroenteropancreatic tumors. JOP: Journal of the Pancreas, 2006, 7, 145-9.	1.5	1
117	Tumor M2-pyruvate kinase: Is it a new useful marker for neuroendocrine tumors?. Gastroenterology, 2003, 124, A421.	1.3	0
118	Warm water and oil for the difficult colon. Gastrointestinal Endoscopy, 2009, 69, 391.	1.0	0
119	Metastatic 5-mm rectal neuroendocrine carcinoma. Digestive and Liver Disease, 2011, 43, e25.	0.9	0
120	Everolimus for the treatment of advanced pancreatic neuroendocrine tumors. Clinical Investigation, 2012, 2, 1123-1131.	0.0	0
121	Type 3 Gastric Neuroendocrine Neoplasms: Relationship between Tumor Size, Ki67 and Clinical Outcome. Gastroenterology, 2017, 152, S670.	1.3	0
122	Heterogeneity of Type 1 Gastric Neuroendocrine Neoplasms. Gastroenterology, 2017, 152, S669.	1.3	0
123	Therapy for Locoregional Disease: Stomach/Duodenum, Colon/Rectum. , 2018, , 219-234.		0
124	CAPTEM or FOLFIRI as second-line therapy in neuroendocrine carcinomas and exploratory analysis of predictive role of PET imaging and biological markers (SENECA study). Annals of Oncology, 2018, 29, viii477-viii478.	1.2	0
125	Chromogranin A usefulness in small non-functioning pancreatic neuroendocrine tumors surgical management. Surgery, 2019, 166, 952.	1.9	0
126	A cure model survival analysis of patients affected by small intestinal neuroendocrine neoplasms: the Bologna ENETS center experience. Endocrine, 2019, 64, 702-707.	2.3	0

#	Article	IF	Citations
127	Siblings Diagnosed With Primary Neuroendocrine Tumor of the Left Hepatic Duct. ACG Case Reports Journal, 2019, 6, e00104.	0.4	0
128	Adjuvant chemotherapy in nonmetastatic goblet cell carcinomas: A population-based analysis.. Journal of Clinical Oncology, 2021, 39, e16203-e16203.	1.6	0
129	Large cell neuroendocrine carcinoma of the lung: Prognostic factors to predict clinical outcomes.. Journal of Clinical Oncology, 2021, 39, e20515-e20515.	1.6	0
130	Prophylactic cholecystectomy is not mandatory in patients candidate to the resection for small intestine neuroendocrine neoplasms: a propensity score-matched and cost-minimization analysis. Updates in Surgery, 2021, , 1.	2.0	0
131	New WHO classification for pancreatic endocrine tumors: Is time to leave the previous one?. Journal of Clinical Oncology, 2012, 30, e14647-e14647.	1.6	0
132	Abstract LB-256: Impact of metformin on progression-free survival in diabetic patients with advanced pancreatic neuroendocrine tumors (pNETs) receiving everolimus and/or somatostatin analogues: A sensitivity analysis of the PRIME-NET (pancreatic multicentric, retrospective, italian metformin) study. , 2017, , .		0
133	Effect of intravenous infusion of amino acids on pancreatic secretion. Hepato-Gastroenterology, 2002, 49, 822-4.	0.5	0
134	Total metabolic tumor volume on 18F-fluorodeoxyglucose-positron emission tomography ([18F]-FDG-PET) scan: A potential prognostic factor in extensive-stage small cell lung cancer.. Journal of Clinical Oncology, 2022, 40, 8574-8574.	1.6	0